BiotechTubeBiotechTube
Home/Pipeline/AP-202

AP-202

Advanced Solid Tumors

Phase 1/2Active, dose expansion

Key Facts

Indication
Advanced Solid Tumors
Phase
Phase 1/2
Status
Active, dose expansion
Company
Advance Pharmaceutical

About Advance Pharmaceutical

Advance Pharmaceutical is dedicated to translating scientific discoveries into transformative medicines for patients with high unmet medical needs. The company's core technology enables the precise targeting of disease pathways, particularly in oncology and genetic disorders. With a robust pipeline of candidates in various stages of development and a strong leadership team, the company is strategically positioned for growth. Its focus on both internal development and strategic partnerships aims to accelerate the delivery of new therapies to market.

View full company profile

Therapeutic Areas

OncologyRare Diseases

Other Advanced Solid Tumors Drugs

DrugCompanyPhase
SHR-1701Jiangsu Hengrui MedicinePhase 1
BAY 1895344BayerPhase 1
HS-10342Hansoh PharmaPhase 1/2
ANKTIVA® + M-ceNKImmunityBioPhase 1
DFTX-101Definium TherapeuticsPhase 1/2
REC-617Recursion PharmaceuticalsPhase 1/2
ZW220ZymeworksPreclinical
NX-1607Nurix TherapeuticsPhase 1a
IMA402 (TCR Bispecific)ImmaticsPhase 1
IMA403 (TCR Bispecific)ImmaticsPre-clinical
BCA101Bicara TherapeuticsPhase 1
AN4005Adlai NortyePreclinical